Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on July 30, 2007

Hypertension. 2007
Published online before print July 30, 2007, doi: 10.1161/HYPERTENSIONAHA.107.094821
A more recent version of this article appeared on September 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
50/3/512    most recent
HYPERTENSIONAHA.107.094821v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fink, G.
Right arrow Articles by Watts, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fink, G.
Right arrow Articles by Watts, S.
Related Collections
Right arrow Animal models of human disease
Right arrow Other hypertension

Submitted on May 23, 2007
Revised on June 6, 2007

Chronic Activation of Endothelin B Receptors. New Model of Experimental Hypertension

Gregory Fink*; Melissa Li; Yanny Lau; John Osborn; and Stephanie Watts

From the Department of Pharmacology and Toxicology (G.F., M.L., Y.L., S.W.), Michigan State University, East Lansing; and the Department of Integrative Biology and Physiology (J.O.), University of Minnesota Medical School, Minneapolis.

* To whom correspondence should be addressed. E-mail: finkg{at}msu.edu.

Abstract—Endothelin (ET) exerts powerful pressor actions primarily through activation of the ETA receptor subtype. The ETB receptor (ETBR) subtype, on the other hand, is generally thought to initiate physiological actions that decrease arterial pressure. Such actions include clearing ET from the bloodstream, initiating endothelium-mediated vasodilation, and facilitating renal sodium and water excretion. The effect of long-term activation of the ETBR on arterial pressure, however, never has been directly tested. In this study we evaluated cardiovascular responses to chronic (5-day) activation of ETBR in male rats using continuous intravenous infusion of the selective agonist sarafotoxin 6c. Surprisingly, we found that sarafotoxin 6c caused a sustained increase in arterial pressure that rapidly reversed on termination of infusion. The hypertension was associated with increased renal excretion of sodium and water and decreased plasma volume. Alterations in daily sodium intake did not affect the magnitude of the hypertension. Hemodynamic studies revealed a decreased cardiac output and increased total peripheral resistance during sarafotoxin 6c infusion. Infusion of sarafotoxin 6c caused a small increase in plasma ET levels. Nevertheless, the hypertension was not affected by coadministration of a selective ETA receptor antagonist (atrasentan) but was completely prevented by treatment with a combined ETA receptor and ETBR antagonist (A186280). These experiments reveal for the first time that chronic activation of ETBR in rats causes sustained hypertension.


Key words: endothelin • ETB receptor • salt • hemodynamics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
N. R. Tykocki, C. E. Gariepy, and S. W. Watts
Endothelin ETB Receptors in Arteries and Veins: Multiple Actions in the Vein
J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 875 - 881.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Li, X. Dai, S. Watts, D. Kreulen, and G. Fink
Increased superoxide levels in ganglia and sympathoexcitation are involved in sarafotoxin 6c-induced hypertension
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2008; 295(5): R1546 - R1554.
[Abstract] [Full Text] [PDF]